乳腺癌区域淋巴结照射:VMAT 与三维计划剂量学差异量化
该研究对比50例需综合区域淋巴结照射的乳腺癌患者三维计划与VMAT计划的剂量学差异。VMAT在靶区覆盖、热点、额外治疗体积及肩背部剂量等多指标上优于三维计划;作者认为VMAT不应要求与三维计划对比才获保险覆盖。
要点
- VMAT靶区接受98%处方剂量(5000 cGy)的平均百分比为98.9%,三维计划为95.4%(P < .01)。
- VMAT平均靶区热点为5450 cGy,三维计划为7200 cGy(P < .01)。
- 三维计划平均额外治疗体积近VMAT两倍(5.3% vs 2.7%,P < .01)。
核心结论
- 对于需综合区域淋巴结照射的乳腺癌患者,VMAT在多个指标上优于三维计划。
- VMAT的保险覆盖不应要求提供三维对比计划。
研究设计与样本
- 对50例需综合区域淋巴结照射的乳腺癌患者,比较VMAT与三维计划的剂量学差异。
- 比较指标包括靶区剂量、处方等剂量线适形性、计划热点、正常组织剂量体积指标及肩背部剂量。
主要发现
- 三维计划靶区接受98%处方剂量(5000 cGy)的平均百分比为95.4% vs VMAT为98.9%(P < .01)。
- 三维计划平均靶区热点为7200 cGy vs VMAT为5450 cGy(P < .01)。
- 三维计划平均额外治疗体积近VMAT两倍(5.3% vs 2.7%,P < .01)。
- VMAT计划肩部和背部剂量更低。
- VMAT计划全身接受处方100%至130%剂量阈值的平均总体积更低,且机构正常组织剂量约束指标通常更优。
关键数值与推荐
- 靶区覆盖:三维计划平均95.4% vs VMAT 98.9%接受98%处方剂量(5000 cGy)(P < .01)。
- 靶区热点:三维计划平均7200 cGy vs VMAT 5450 cGy(P < .01)。
- 额外治疗体积:三维计划平均5.3% vs VMAT 2.7%(P < .01)。
临床怎么用
- 原文结论为VMAT在需综合区域淋巴结照射的乳腺癌患者多个指标上优于三维计划。
- 原文提出VMAT的保险覆盖不应要求三维对比计划。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We quantify dosimetric differences between 3-dimensional (3D) planning and volumetric modulated arc therapy (VMAT) in breast cancer patients requiring comprehensive regional nodal irradiation (CRNI). Target volume dose, prescription isodose conformality to target volumes, plan hotspots, normal tissue dose-volume metrics, and back and shoulder dose were compared for VMAT and 3D plans of 50 patients. Metrics used to compare VMAT plans with 3D plans included the percentage of primary clinical target volumes (CTVs) receiving 98% of a prescription dose of 5000 cGy, CTV dose hotspots, the extra treatment volume (ETV), and the portion of the patient's body receiving 90% of the CTV prescription dose (excluding the primary target volume). Superior values for these metrics were found for VMAT plans when compared to 3D plans. The mean percentage of the target volume receiving 98% of the prescription dose of 3D plans was 95.4% versus 98.9% among VMAT plans (P < .01). The mean target volume hotspot of 3D plans was 7200 cGy versus 5450 cGy for VMAT plans (P < .01). A mean ETV found for 3D plans was nearly double that found among VMAT plans (5.3% vs 2.7%, P < .01). VMAT plans resulted in lower doses to the shoulder and back. Mean total body volumes of VMAT plans were lower for dose thresholds of 100% to 130% of the prescription. VMAT plans generally had superior values for institutional normal tissue dose constraints. VMAT is superior to 3D planning across multiple metrics for breast cancer patients requiring CRNI. Insurance coverage for VMAT should not require 3D comparison plans.
引用
- Kendall R, Robinson T, Reed V, et al. Why is Volumetric Modulated Arc Therapy Not Considered the Standard of Care for Locoregional Radiation Therapy for Breast Cancer Patients? Adv Radiat Oncol. 2025. PMID: 40264855. doi:10.1016/j.adro.2025.101728
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。